Akademik Veri Yönetim Sistemi
ARCHIVES OF DERMATOLOGICAL RESEARCH, cilt.317, sa.1, 2025 (SCI-Expanded, Scopus)
Although omalizumab is the recommended second-line treatment option in chronic spontaneous urticaria (CSU), there is no clear recommendation on how long the treatment should be given and how it should be discontinued. In this study, we aimed to compare the impact of two different protocols used in omalizumab treatment discontinuation on the quality of life and disease control of CSU patients. Fifty-two patients with CSU who were treated with omalizumab between 2023 and 2024 were included. After at least six doses of omalizumab therapy, treatment intervals of the patients with well-controlled disease (UCT >= 12) were continued in 2 different protocols with the joint decision of the patient-physician. In the first group (n = 24), standard dose omalizumab treatment was continued for every 4 weeks, in the second group (n = 28), treatment intervals were extended to a maximum of 8 weeks by increasing one week in each administration. Disease control was assessed using urticaria control test (UCT), and quality of life was assessed using chronic urticaria quality of life questionnaire (CU-QoL), satisfaction scale (numerical analog scale from 0 to 10) and dermatology quality of life questionnaire (DLQI). Both groups were similar regarding baseline predictive laboratory parameters and demographics before omalizumab treatment. After six doses with omalizumab, the first group without treatment interval prolongation had similar UCT [14.5 (13.3-16) vs. 14.5 (13-16); p = 0.894], CU-QoL [11 (1-26) vs. 14 (0.5-25.8); p = 0.926] and DLQI [1.5 (1-7.3) vs. 2 (0-4); p = 0.407] results when compared the second group with omalizumab treatment interval prolongation. At the same time, the results obtained from the satisfaction scale were similar in both groups [8 (7.3-10) vs. 9(8-10); p = 0.405].Our results showed that treatment interval prolongation is well tolerated in selected patients with CSU and has similar effects on disease control and patient quality of life compared to standard therapy.